The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Forecasted Market Value Of The Renin-Angiotensin-System (RAS)-Acting Agents Market Across 2026–2030?
The market size for renin-angiotensin-system (ras)-acting agents has experienced significant expansion in recent years. It is anticipated to grow from $6.11 billion in 2025 to $6.44 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. The historical increase in this market can be attributed to several factors including the high prevalence of hypertension, the growth of the aging population, the widespread adoption of ACE inhibitors, an increase in cardiovascular screening, and the affordability of generic drugs.
The market size for renin-angiotensin-system (ras)-acting agents is projected to experience robust growth in the coming years. It is anticipated to expand to $7.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. This projected growth can be attributed to several factors, including the increasing burden of chronic kidney disease, a rising demand for cardiometabolic drugs, improved patient adherence to treatments, market expansion into emerging regions, and the approval of new combination therapies. Significant trends expected during this forecast period involve the growing adoption of combination antihypertensive treatments, the development of long-acting cardiovascular drugs, a heightened focus on renal protection therapies, the expansion of generic RAS drug production, and a general shift towards fixed-dose combinations.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Renin-Angiotensin-System (RAS)-Acting Agents Market?
The expanding occurrence of hypertension is anticipated to fuel the expansion of the renin-angiotensin system (RAS)-acting agents market. Hypertension, also known as elevated blood pressure, is a persistent health issue characterized by persistently excessive blood pressure against artery walls. The rise in hypertension cases is often linked to poor dietary habits, specifically diets rich in salt and processed items, which lead to higher blood pressure and stress on the cardiovascular system. Renin-angiotensin system (RAS)-acting agents assist in reducing hypertension rates by managing blood pressure through the inhibition of angiotensin II. This hormone normally constricts blood vessels and increases fluid retention, but by blocking it, RAS-acting agents promote vasodilation and lower blood pressure. For example, in September 2025, the World Health Organization, a Switzerland-based intergovernmental organization, reported that an estimated 1.4 billion adults globally aged 30–79 were living with hypertension in 2024, constituting about 33% of individuals in this age group. Hence, the growing prevalence of hypertension is a significant driver for the renin-angiotensin system (RAS)-acting agents market.
What Segmentation Levels Are Considered In The Renin-Angiotensin-System (RAS)-Acting Agents Market?
The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –
1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes
2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril
2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan
3) By Renin Inhibitors: Aliskiren
4) By Aldosterone Antagonists: Spironolactone, Eplerenone
5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)
What Trends Are Projected To Affect The Renin-Angiotensin-System (RAS)-Acting Agents Market?
Leading companies in the renin-angiotensin system (RAS)-acting agents market are concentrating on developing innovative renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors. This focus aims to boost efficacy, minimize adverse effects, enhance patient adherence, and address conditions like hypertension, heart failure, and kidney diseases. An angiotensin-converting enzyme (ACE) inhibitor is a medication designed to reduce blood pressure by inhibiting the enzyme responsible for converting angiotensin I to angiotensin II, a substance known to constrict blood vessels. For example, in November 2023, Proveca Ltd., a UK-based pharmaceutical company, received a grant from the European Commission for pediatric use marketing authorization (PUMA) for its Aqumeldi (enalapril maleate) orodispersible tablets. These tablets are indicated for treating heart failure in children from birth to less than 18 years. Aqumeldi functions as an angiotensin-converting enzyme (ACE) inhibitor, treating pediatric heart failure by blocking the angiotensin-converting enzyme (ACE), which prevents the conversion of angiotensin I to angiotensin II, thereby promoting blood vessel relaxation, improving blood flow, and reducing the heart’s workload.
Which Leading Firms Are Contributing To The Growth Of The Renin-Angiotensin-System (RAS)-Acting Agents Market?
Major companies operating in the renin-angiotensin-system (ras)-acting agents market are Novartis AG, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences Limited
Read the full renin-angiotensin-system (ras)-acting agents market report here:
Which Regions Are Projected To Dominate The Renin-Angiotensin-System (RAS)-Acting Agents Market In The Coming Years?
North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (ras)-acting agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Renin-Angiotensin-System (RAS)-Acting Agents Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp
Browse Through More Reports Similar to the Global Renin-Angiotensin-System (RAS)-Acting Agents Market 2026, By The Business Research Company
Angiotensin Receptor Blockers Arbs Market Report 2026
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Inotropic Agents Market Report 2026
https://www.thebusinessresearchcompany.com/report/inotropic-agents-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model